Simplexia develops a vaccine against genital herpes. The project originates from the Sahlgrenska Academy, where three researchers have identified a protein which can be used as a vaccine against herpes simplex virus type 2 (HSV-2), i.e. genital herpes. In the spring of 2009 the project was brought into the incubator at Göteborg International Bioscience Business School (GIBBS) and in 2011 it became part of the business incubator at Sahlgrenska Science Park.
Top news
- Simplexia receives continued financing from VINNOVA (2011-11-23)
- Simplexia presents at Park Annual 2011 (2011-09-08) (Link in Swedish)
- Simplexia receives pre-seed grant from the Novo Nordisk Foundation (2011-08-22)
- Simplexia receives funding from VINNOVA (2011-05-10) (In Swedish)